What this study is
The goal of this clinical trial is to learn whether a 30-day structured wellness program may support physical and emotional well-being in adults who are already taking a GLP-1 or dual GIP/GLP-1 medication for an FDA-approved indication. The study does not evaluate the GLP-1 medication itself or make changes to participants' medication treatment.
The main questions it aims to answer are:
1. Are there changes in participants' physical and emotional well-being after completing the 30-day wellness program? 2. Are there changes in areas such as mood, anxiety, functioning, mindfulness, self-compassion, eating-related behaviors, pain, and positive wellness?
Participants will:
1. Complete online questionnaires before and after the program. 2. Follow the WILD 5 Wellness program for 30 days, which includes daily practices related to exercise, mindfulness, sleep, social connection, and nutrition. 3. Complete a brief online tracking form each day during the 30-day program.
What's being tested
- WILD 5 Wellness Program
Intervention · BEHAVIORAL
A 30-day structured wellness program that includes daily practices in five areas: exercise, mindfulness, sleep, social connection, and nutrition. Participants complete the wellness practices independently and complete daily online tracking during the 30-day program.
Study details
- Sponsor
- Saundra Jain
- Conditions
- Wellness
- Enrolling
- 200 people
- Starts
- 2026-09-15
- Est. completion
- 2027-10
- Design
- Open-label, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age 18 years or older. Able to speak, read, and understand English. Interested in supporting physical and emotional well-being. Access to a reliable Internet-enabled device, such as a computer, smartphone, or tablet.
- Possess basic skills needed to complete online study forms. Currently prescribed and taking a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist by a licensed healthcare practitioner.
- Report that the medication was prescribed for an FDA-approved indication, such as type 2 diabetes mellitus, chronic weight management for obesity or overweight with at least one weight-related condition, moderate-to-severe obstructive sleep apnea in adults with obesity, or another FDA-approved cardiometabolic indication.
- Willing to complete online consent, registration, program measures, and daily tracking forms.
- Willing to participate in the 30-day WILD 5 Wellness program delivered as part of the GLOW Study.
You can't join if
- Under 18 years of age. Unable to speak, read, or understand English. Do not have access to a reliable Internet-enabled device. Do not possess basic skills needed to complete online study forms. Not currently prescribed and taking a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist by a licensed healthcare practitioner.
- Report that the medication was not prescribed for an FDA-approved indication. Pregnant or planning to become pregnant in the next 30 days. Currently have thoughts about harming themselves or someone else. Currently experiencing symptoms suggestive of active psychosis. Unwilling or unable to complete the required online study forms or participate in the 30-day
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openThe GLOW Study
The Colony, Texas, United States
- Saundra Jain, MA, PsyD, LPC · Contact888-252-7806saundrajain@gmail.com
- Contactsaundrajain@gmail.com
- Saundra Jain, MA, PsyD, LPC · Principal investigator
- Rakesh Jain, MD, MPH · Principal investigator
Recruiting
Study team
Sponsor
Saundra Jain
Study ID GLOW2026
Principal investigator
Saundra Jain, MA, PsyD, LPC
The University of Texas at Austin School of Nursing
Principal investigator
Rakesh Jain, MD, MPH
Texas Tech University Health Sciences Center School of Medicine - Permian Basin
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.